Julio D Duarte, Pharm.D., Ph.D., FAHA
Associate Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-8132
Business Email:
juliod@ufl.edu
About Julio D Duarte
Julio Duarte is an associate professor of pharmacy and medicine as well as Co-Director of the UF Center for Pharmacogenomics and Precision Medicine. He received his Pharm.D. as well as his Ph.D. in clinical pharmaceutical sciences from the University of Florida. He was an assistant professor at the University of Illinois at Chicago (UIC) and Co-Director of the University of Illinois Hospital Personalized Medicine Program until returning to UF in 2015. Dr. Duarte has served as a grant reviewer for both NIH and U.S Department of Defense. He is an elected Fellow of the American Heart Association and has received awards for his research from both UIC and UF. Dr. Duarte also serves as Graduate Coordinator of the Clinical Pharmaceutical Sciences concentration within the College of Pharmacy’s graduate program.
Accomplishments
Faculty Diversity, Inclusion, and Health Equity Award
2023
·
University of Florida College of Pharmacy
Fellow
2017
·
American Heart Association
Outstanding Clinical Research Award
2017
·
University of Florida College of Pharmacy
Hans Vahlteich Research Scholar
2013
·
College of Pharmacy, University of Illinois at Chicago
Teaching Profile
Courses Taught
2017-2018,2020-2023
PHA5878C Pt Care 3: Cv and Pulm
2020,2022-2024
PHA6910 Supervised Research
2017,2019-2024
PHA7980 Research for Doctoral Dissertation
2017,2019-2023,2023-2024
PHA7979 Advanced Research
2020-2023
PHA6935 Selected Topics in Pharmacy
2017-2024
PHA5012 App Personalized Med
2019-2021
PHA6135 Clinical Applications of Precision Medicine: Pharmacogenomics
2018,2024
PHA6449 Pharmacogenomic and Genomic Data Analysis
2018,2021-2024
PHA5876C Pt Care 8 Complex Pts
2017,2022-2024
PHA4914 Undergraduate Research in Pharmacotherapy and Translational Research
2020-2021
PHA5040 Pharmacogenomic Literature Assessment
2021
PHA6894 Introduction to Graduate Studies
2021-2024
PHC6598 Foundations in Precision Medicine: Genetic Epidemiology
2023-2024
PHA6938 Research Seminar
2023
PHA6185 Life Cycle of a Drug
2024
PHA7900 Journal Club in Pharmaceutical Research
Research Profile
Dr. Duarte’s research primarily focuses on: (1) the biological mechanisms underlying left heart failure progression, including development of pulmonary hypertension and (2) the clinical implementation of preemptive pharmacogenetic testing, particularly in medically underserved patient populations. His NIH-funded laboratory conducts translational research attempting to discover genomic predictors of drug response, as well as using genomics and transcriptomics to identify novel targets for future drug development.
Open Researcher and Contributor ID (ORCID)
0000-0001-9766-4038
Publications
2024
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score.
Journal of the American College of Cardiology.
83(15):1370-1381
[DOI] 10.1016/j.jacc.2024.02.015.
[PMID] 38599713.
2024
Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment.
Frontiers in pharmacology.
15
[DOI] 10.3389/fphar.2024.1384667.
[PMID] 38595920.
2024
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients
Clinical and Translational Science.
17(1)
[DOI] 10.1111/cts.13692.
[PMID] 38013396.
2023
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Clinical Pharmacology & Therapeutics.
114(2):275-287
[DOI] 10.1002/cpt.2957.
[PMID] 37303270.
2023
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
113(3):615-623
[DOI] 10.1002/cpt.2776.
[PMID] 36306392.
2023
Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations
Pharmacogenomics.
24(6):303-314
[DOI] 10.2217/pgs-2023-0014.
2022
CYP2C19
Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
Journal of the American Heart Association.
11(4)
[DOI] 10.1161/jaha.121.024159.
2022
Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing.
Pharmacogenomics.
23(2):85-95
[DOI] 10.2217/pgs-2021-0109.
[PMID] 35001645.
2022
Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.
Frontiers in genetics.
13
[DOI] 10.3389/fgene.2022.1085994.
[PMID] 36712853.
2022
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers
The Pharmacogenomics Journal.
22(1):62-68
[DOI] 10.1038/s41397-021-00257-1.
[PMID] 34642472.
2022
Patients’ Perspectives of Factors That Influence Pharmacogenetic Testing Uptake: Enhancing Patient Counseling and Results Dissemination.
Journal of personalized medicine.
12(12)
[DOI] 10.3390/jpm12122046.
[PMID] 36556266.
2022
Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease.
American heart journal plus : cardiology research and practice.
17
[DOI] 10.1016/j.ahjo.2022.100152.
[PMID] 35959094.
2022
β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery.
Clinical and translational science.
15(3):619-625
[DOI] 10.1111/cts.13178.
[PMID] 34713976.
2021
County-level longitudinal clustering of COVID-19 mortality to incidence ratio in the United States.
Scientific reports.
11(1)
[DOI] 10.1038/s41598-021-82384-0.
[PMID] 33542313.
2021
Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects.
Frontiers in genetics.
12
[DOI] 10.3389/fgene.2021.701405.
[PMID] 34408773.
2021
IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias.
Blood.
137(9):1208-1218
[DOI] 10.1182/blood.2020005944.
[PMID] 33181835.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
109(3):705-715
[DOI] 10.1002/cpt.2039.
[PMID] 32897581.
2021
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing
Genetics in Medicine.
23(12):2335-2341
[DOI] 10.1038/s41436-021-01269-9.
[PMID] 34282303.
2021
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.
Pharmacotherapy.
41(12):978-987
[DOI] 10.1002/phar.2626.
[PMID] 34569641.
2021
Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines.
Clinical and translational science.
14(5):1841-1852
[DOI] 10.1111/cts.13032.
[PMID] 33955180.
2021
Pharmacogenetics to guide cardiovascular drug therapy.
Nature reviews. Cardiology.
18(9):649-665
[DOI] 10.1038/s41569-021-00549-w.
[PMID] 33953382.
2021
Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease
Journal of the American Heart Association.
10(11)
[DOI] 10.1161/jaha.120.020633.
2020
Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
Journal of cardiovascular pharmacology.
75(3):250-258
[DOI] 10.1097/FJC.0000000000000779.
[PMID] 31895871.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal.
20(5):724-735
[DOI] 10.1038/s41397-020-0162-5.
[PMID] 32042096.
2019
Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
Clinical and translational science.
12(4):416-423
[DOI] 10.1111/cts.12632.
[PMID] 30821899.
2019
Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-55700-y.
[PMID] 31862991.
2018
Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.
JAMA.
320(16):1670-1677
[DOI] 10.1001/jama.2018.14955.
[PMID] 30357299.
2018
CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue.
Clinical pharmacology and therapeutics.
104(5):974-982
[DOI] 10.1002/cpt.1032.
[PMID] 29349771.
2018
Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.
Pulmonary circulation.
8(2)
[DOI] 10.1177/2045894018773049.
[PMID] 29718770.
2017
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Clinical pharmacology and therapeutics.
101(5):675-683
[DOI] 10.1002/cpt.558.
[PMID] 28032893.
2017
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Clinical and translational science.
10(3):143-146
[DOI] 10.1111/cts.12456.
[PMID] 28294551.
2016
Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure
Journal of cardiac failure.
22(9):692-699
[DOI] 10.1016/j.cardfail.2015.12.016.
[PMID] 26721774.
2016
Clopidogrel pharmacogenetics: from evidence to implementation.
Future cardiology.
12(5):511-4
[DOI] 10.2217/fca-2016-0045.
[PMID] 27539287.
2016
Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease
PLOS ONE.
11(9)
[DOI] 10.1371/journal.pone.0163013.
[PMID] 27636371.
2016
Implementation of Inpatient Models of Pharmacogenetics Programs
American Journal of Health-System Pharmacy.
73(23):1944-1954
[DOI] 10.2146/ajhp150946.
[PMID] 27864202.
2016
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.
Clinical and translational science.
9(5):233-245
[DOI] 10.1111/cts.12404.
[PMID] 27214750.
2015
Genes Affecting Warfarin Response-Interactive Or Additive?
Journal of clinical pharmacology.
55(3):258-260
[DOI] 10.1002/jcph.425.
[PMID] 25385663.
2015
Genetic Associations With Warfarin Response in Patients Receiving Genotype-Guided Dosing.
Clinical Pharmacology & Therapeutics.
97(1)
2015
Pharmacogenomics of hypertension and heart disease.
Current hypertension reports.
17(9)
[DOI] 10.1007/s11906-015-0586-5.
[PMID] 26272307.
2014
Barriers To Implementing Pharmacogenetic Testing in An Urban Population.
Pharmacotherapy.
34(10)
2014
Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.
Expert review of cardiovascular therapy.
12(11):1289-303
[DOI] 10.1586/14779072.2014.970180.
[PMID] 25340283.
2013
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
The pharmacogenomics journal.
13(3):257-63
[DOI] 10.1038/tpj.2012.4.
[PMID] 22350108.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Feasibility of implementing a comprehensive warfarin pharmacogenetics service.
Pharmacotherapy.
33(11):1156-64
[DOI] 10.1002/phar.1329.
[PMID] 23864527.
2013
Personalized medicine in cardiology: the time for genotype-guided therapy is now.
Future cardiology.
9(4):459-64
[DOI] 10.2217/fca.13.35.
[PMID] 23834684.
2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-56.
[PMID] 22440088.
2010
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
Pharmacogenetics and genomics.
20(8):516-9
[DOI] 10.1097/FPC.0b013e32833b5958.
[PMID] 20555294.
2010
Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics.
Expert review of cardiovascular therapy.
8(6):793-802
[DOI] 10.1586/erc.10.27.
[PMID] 20528637.
Grants
Jul 2023
ACTIVE
Omega-3 fatty acids and myocardial inflammation in HFpEF
Role: Co-Investigator
Funding: AMER HEART ASSOCIATION
Jul 2023
ACTIVE
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
May 2023
ACTIVE
Training Program for Applied Research and Development in Genomic Medicine
Role: Principal Investigator
Funding: NATL INST OF HLTH NHGRI
Jun 2022
ACTIVE
Genetic Associations of Ischemic Heart Disease and Symptoms Among Diverse Postmenopausal Women
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2021
ACTIVE
Preemptive pharmacogenetic testing in medically underserved populations
Role: Principal Investigator
Funding: NATL INST OF HLTH NHGRI
Jul 2021
ACTIVE
Using Artificial Intelligence to Identify Patients Most Likely to Benefit from Preemptive Pharmacogenetic Testing
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jul 2020
– Mar 2022
Together Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Nov 2015
– Mar 2020
Improving treatment personalization for pulmonary hypertension associated with diastolic heart failure
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
Education
Ph.D.
2010
·
University of Florida
Pharm.D.
2006
·
University of Florida
Contact Details
Phones:
- Business:
- (352) 273-8132
Emails:
- Business:
- juliod@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD RM PG 21
GAINESVILLE FL 32610